RxDoctor Payments Data

Mikayla Rorar

Nurse Practitioner · Akron, OHNPI 1417685033

Payments from drug & device makers

$1,813in general payments, 2019–2025

Across 33 payments — averaging $54.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Sumitomo Pharma America, Inc.$199
  • Boston Scientific$183
  • Teleflex LLC$137
  • Convatec Inc.$24
  • Tolmar, Inc.$17
  • plus $16 from 1 others

What the payments were for

  • Travel & lodging$73440%
  • Food & beverage$1,07960%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,813 in reported general payments places this provider in the 90th percentile of 4,700 nurse practitioner providers in Ohio.

See all nurse practitioner providers in Ohio

Medicare billing

Part B allowed, 2024
$24,210
Medicare patients
161
Services billed
1,580

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron268$222,869
GemtesaVibegron32$27,942
Mirabegron ErMirabegron25$10,963
Estradiol97$5,919
Methenamine Hippurate56$5,774
Trospium Chloride84$5,646
Tamsulosin Hcl374$5,556
Testosterone19$4,168
Solifenacin Succinate59$3,291
Trospium Chloride ErTrospium Chloride20$3,191
Finasteride196$2,481
Tolterodine Tartrate ErTolterodine Tartrate12$1,231
Potassium Citrate ErPotassium Citrate11$1,092
Oxybutynin Chloride ErOxybutynin Chloride50$1,052
Testosterone Cypionate15$917

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$16$222,869268 claims
Sumitomo Pharma America, Inc.Gemtesa$199$27,94232 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,700 nurse practitioner providers in Ohio.

Other nurse practitioner in Akron

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →